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A B S T R A C T
It is proposed that overexpression of P-glycoprotein (P-gp), encoded by the ABC subfamily B member 1
(ABCB1) gene, is involved in resistance to antiepileptic drugs (AEDs) in about 30% of patients with
epilepsy. Genetic variation and haplotype patterns are population speciﬁc which may cause different
phenotypes such as response to AEDs. Although several studies examined the link between the common
polymorphisms in the ABCB1 gene with resistance to AEDs, the results have been conﬂicting. This
controversy may be caused by the effect of some confounders such as ethnicity and polytherapy.
Moreover, expression of the ABCB1 gene is under the control of pregnane X receptor (PXR). Evidence
showed that PXR gene contribute to the response to treatment. The aim of this study was to assess the
association of ABCB1 and PXR genetic polymorphisms with response to the carbamazepine (CBZ) or
sodium valproate (VPA) monotherapy in epilepsy. Genotypes were assessed in 685 Chinese, Indian, and
Malay epilepsy patients for ABCB1 (C1236T, G2677T, C3435T) and PXR (G7635A) polymorphisms. No
association between these polymorphisms and their haplotypes, and interaction between them, with
response to treatment was observed in the overall group or in the Chinese, Indian, andMalay subgroups.
Our data showed that these polymorphisms may not contribute to the response to CBZ or VPA
monotherapy treatment in epilepsy.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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About one third of epilepsy patients do not respond to
antiepileptic drugs (AEDs).1 Some studies showed that over
expression of P-glycoprotein (P-gp) in brain tissue contributes to
the resistance toAEDs.2 P-gp is an efﬂux transporter that limits the
cellular uptake levels of various drugs in intestine, brain, and
other tissues.3 It is encoded by the ABC subfamily B member 1
(ABCB1) transporter gene. The human ABCB1 gene is located at
chromosome 7p21, composed of 29 exons (http://
www.ncbi.nlm.nih.gov). The C1236T (rs1128503), G2677T/A
(rs2032582), and C3435T (rs1045642) loci are the most com-
monly studied genetic variants in the ABCB1 gene. C1236T and
C3435T polymorphisms are synonymous loci which alter the GGC
codon to GGT (Gly412Gly) and the ATC codon to ATT (Ile1145Ile),
respectively. However, the ABCB1 G2677T/A polymorphism is a
non-synonymous locus resulting in amino acid exchanges* Corresponding author. Tel.: +60 3 6255419; fax: +60 3 79674791.
E-mail address: batoolsadat@yahoo.com (B.S. Haerian).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.008(Ala893Ser or Ala893Thr). Among these three loci, C3435T
polymorphism has received more attention as a critical variant
in AEDs resistance.4–7 Several genetic studies have attempted to
link the ABCB1 gene common genetic variants to the resistance to
AEDs, but the results have been conﬂicting. Our meta-analysis
involving 6755 Asian and Caucasian patients did not conﬁrm this
association in the total study population or in the ethnic
subgroups.8–11 Therefore, it was suggested that controversy
between the studies may be caused by the effect of some
confounders such as ethnicity and polytherapy.8
It is proposed that linkage disequilibrium (LD) of the silent
C3435T with other ABCB1 variants in a haplotype block may link
with resistance to AEDs.12 Haplotype and LD patterns are
population speciﬁc, most probably shaped by evolutionary forces
such as natural selection in ancestral populations in various
geographical regions. Diversity in the haplotype block structures
and LD patterns is high in European and East Asian populations.
This diversity may cause crucial changes in the complex
interaction of genetic and environmental factors in producing
some phenotypes such as susceptibility to disease and response to
pharmacological agents.13–15 Therefore, some studies examinedvier Ltd. All rights reserved.
B.S. Haerian et al. / Seizure 20 (2011) 387–394388the association of the ABCB1 haplotype derived from C1236T,
G2677T/A, and C3435T in response to AEDs in different popula-
tions, but results were inconsistent.9,11,16–24
Evidence showed that the ABCB1 gene expression is under the
control of pregnane X receptor (PXR). The PXR is activated by a
broad range of compounds including steroids, antibiotics, and
drugs. Once activated, it binds cognate transcription factor
response elements which are located in the promoters of target
genes, thereby regulating expression of the involved genes in the
metabolism and transport of xenobiotics including the CYP3A
family and ABCB1 gene. Because of the important role of PXR in
regulation of ABCB1 gene, several studies reasoned that variation
in the PXR gene might contribute to response to treatment. Some
reports showed a strong association between PXR G7635A
(rs6785049) polymorphism with susceptibility to inﬂammatory
bowel disease and Crohn’s disease as well as response to treatment
in the renal transplant recipients.25–28 Therefore, in this study, we
addressed the question of whether ABCB1 C1236T, G2677T/A, and
C3435T and PXR G7635A polymorphisms are associated with the
response to treatment in the Malaysian population with epilepsy,
as well as in the Chinese, Indian, and Malay ethnic subgroups.
2. Methods
2.1. Subjects
The present study is part of an ongoingmulticentre cooperation
between the University of Malaya Medical Centre and the National
University of Malaysia Medical Centre. The study protocol was
approved by the Ethics Committees of both centres. A total of 685
patients with epilepsy who were on carbamazepine (CBZ) or
sodium valproate (VPA) monotherapy were recruited from the
epilepsy clinics and diagnosed by neurologists who were blinded
to the genotype data. Seizures and etiology of epilepsy were
classiﬁed according to the International League Against Epilepsy
guidelines.29 On the basis of new deﬁnitions of treatment
outcomes,30 drug responsiveness was deﬁned as being completely
seizure free for at least 1 year during treatment with either CBZ or
VPA monotherapy, and drug resistance was deﬁned as the
occurrence of seizures over a period of 1 year during treatment
with either CBZ or VPA monotherapy at maximally tolerated
therapeutic dosages.
Epilepsy patients of Chinese, Indian, andMalay ethnicities were
eligible for inclusion if they were on monotherapy of either CBZ or
VPA for at least 1 year. Exclusion criteria included severe adverse
drug reactions, poor compliance with CBZ or VPA, being on other
AED monotherapy such as phenytoin and lamotrigine (LTG) or on
polytherapy with various AEDs, unreliable record of seizure
frequency, signiﬁcant psychiatric comorbidity, history of pseudo-
seizures, alcohol or drug abuse, and presence of progressive or
degenerative neurological or systemic disorders.Written informed
consent was given by all patients or by their guardians in the case
of a child. A standardized extraction template was administered to
collect demographic details and information on seizure types and
frequency, medical history, concomitant drug history, and relevant
family history from the records.
2.2. Genotyping
Genomic DNA was extracted from either whole blood or buccal
swabs by using standard methods. The ABCB1 (C1236T, G2677T/A,
C3435T) and PXR (G7635A) polymorphisms were genotyped by
polymerase chain reaction (PCR)-restriction fragment length
polymorphism (RFLP).28,31,32 PCR and RFLP products were ana-
lyzed by electrophoresis in 2% agarose gels. The results of PCR-RFLP
were conﬁrmed through DNA sequencing of a random selection ofsamples (5%) by using the ABI Prism 3130 Genetic Analyzer
(Applied Biosystems, USA) and ABI Prism Big Dye Terminator v3.1
cycle sequencing kit.
2.3. Statistical methods
All values were presented either as the mean  standard
deviation for continuous data or as frequency for categorical data.
The ages at study and onset of epilepsy were non-normally
distributed variables, examined by the Kolmogorov–Smirnov test.
Therefore, the frequency of these two variables was compared for
drug-resistant and drug-responsive patients by the non-parametric
Mann–Whitney U test or the Kruskal–Wallis rank sum test.
Comparison of distribution of ethnicity, etiology of epilepsy, and
seizure type in overall patients, irrespective of response to CBZ or
VPA, was performed by binary logistic regression test.
The alternative genetic models for C1236 and C3435T poly-
morphisms included alleles (C vs. T) and genotypes for co-
dominant (C/C vs. T/T and C/T vs. T/T), dominant (C/C + C/T vs. T/T),
and recessive (C/C vs. C/T + T/T) models. For simpliﬁcation of the
analysis of genetic models of the triallelic G2677T/A variant, the A
allele was included with the T allele. The alternative genetic
models for the G2677T polymorphism included alleles (G vs. T) and
genotypes for co-dominant (G/G vs. T/T and G/T vs. T/T), dominant
(G/G + G/T vs. T/T), and recessive (G/G vs. G/T + T/T) models.
Alternative genetic models for PXR G7635A locus included co-
dominant (G/G vs. A/A and G/A vs. A/A), dominant (G/G + G/A vs. A/
A), and recessive (G/G vs. G/A + A/A). A goodness-of-ﬁt x2 test with
one degree of freedom was applied to test Hardy–Weinberg
equilibrium (HWE) of the three polymorphisms; p < 0.05 indicated
a lack of agreementwithHWE. Association of alleles and genotypes
with response to CBZ or VPA monotherapy was calculated with
binary logistic regression, adjusted for ethnicity, drug type, gender,
age at recruitment, onset age of epilepsy, seizure type, and etiology
of epilepsy. Haplotype and LD analysis for the three ABCB1
polymorphisms was performed with the Haploview 4.2 program
and corrected for multiple testing by using 100,000 permutations
for individual locus and haplotypes. Bonferroni’s method was used
for correction of multiple comparisons. Two-sided tests of
statistical signiﬁcance were used to determine statistically
signiﬁcant p values (p < 0.05) with the SPSS software package
(ver. 15.0; SPSS, Chicago, IL, USA).
3. Results
3.1. Patient characteristics
A total of 685 epilepsy patients who were on CBZ or VPA
monotherapy participated in this study. Of these 685 patients, 277
(40.4%), 160 (23.4%), and 248 (36.2%) were Chinese, Indians, and
Malays, respectively. About 62% of the recruited patients were on
monotherapy treatment with VPA. The demographic character-
istics of 323 (47%) drug-resistant and 362 (53%) drug-responsive
patients are shown in Table 1. The distribution of ages at study did
not signiﬁcantly differ between drug-resistant and drug-respon-
sive patients in total or among the Chinese, Indian, and Malay
patients. Onset of epilepsy in the overall population as well as in
Chinese drug-resistant patients was signiﬁcantly earlier than the
drug-responsive patients (p = 0.02 and p = 0.04, respectively).
Males were over-represented (p = 0. 013), but this was not
signiﬁcantly different between drug-resistant and drug-responsive
patients or in each ethnic subgroup. Partial seizure was signiﬁ-
cantly more common among drug-resistant patients than drug-
responsive group in the overall (p = 0.003) and in the Malay
subgroup (p < 0.001). Moreover, symptomatic (39%) and crypto-
genic (36%) epilepsy were also more often diagnosed in the
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B.S. Haerian et al. / Seizure 20 (2011) 387–394 389patients. Symptomatic (p < 0.001) and cryptogenic (p = 0.007)
epilepsy were signiﬁcantly more common in drug-resistant than
drug-responsive patients in the overall patients. Similar results
were obtained in the Malays (p < 0.01) but a marginal signiﬁcance
was observed in the Chinese patients (p = 0.05) with symptomatic
epilepsy.
3.2. Allele and genotype associations of ABCB1 and PXR
polymorphisms with response to drug treatment
Table 2 lists the allele and genotype frequencies of the ABCB1
and PXR polymorphisms of the drug-resistant and drug-responsive
patients. In this study, the C1236 allele was less common than the
alternative allele in the overall (43%) or in the Chinese (42.5),
Indians (44.5), and Malays (41.5). In the Chinese (52%) and Malay
(53%) patients, the G2677 allele was more frequent than the minor
allelewhile it was less frequent in the Indians (41%) than the 2677T
allele. The C3435 and G7635 alleles were more frequent than the
alternative alleles in the overall (60.5%) and in each ethnicity
(Chinese 60%, Indians 54.5%, and Malays 65.5%). The ORs adjusted
for ethnicity, gender, age at the recruitment, age at the onset of
epilepsy, seizure type, drug type, and epilepsy etiology were
calculated for alternative genetic models.
ABCB1 C1236 was slightly more frequent in the Chinese (43%)
and Malay (44%) drug-resistant patients as compared to the drug-
responsive patients (43 and 44%, respectively). Similarly, ABCB1
G2677 allele was more frequent in the Chinese (55%) and Malay
(55%) drug-resistance than drug-responsive patients (49 and 51%,
respectively). Unlike the Chinese subgroup, frequency of the
ABCB1 C3435 allele in the Indian (58%) and Malay (60%) drug-
resistant patients was more than drug-responsive patients (48 and
58%, respectively). Finally, unlike the Indian subgroup, frequency
of the PXRG7635 allele in the Chinese (58%) andMalay (64%) drug-
resistant was less than drug-responsive patients (62 and 67%,
respectively). In the Chinese, Indian, and Malay subgroups, no
signiﬁcant association was observed between C1236 [adjusted OR
0.89, 95% CI 0.61–1.30, p = 0. 56, adjusted OR 1.04, 95% CI 0.64–
1.70, p = 0.86, and OR 0.72, 95% CI 0.48–1.09, p = 0. 29,
respectively], G2677 [adjusted OR 0.73, 95% CI 0.50–1.07, p = 0.
11, adjusted OR 1.60, 95% CI 0.97–2.65, p = 0.07, and adjusted OR
0.87, 95% CI 0.58–1.31, p = 0.51, respectively], C3435 [adjusted OR
1.02, 95% CI 0.83–1.75, p = 0.33, adjustedOR 0.69, 95% CI 0.42–1.12,
p = 0.13, and adjusted OR 0.93, 95% CI 0.62–1.40, p = 0.74,
respectively], and G7635 [adjusted OR 1.03, 95% CI 0.71–1.51,
p = 0.86, adjusted OR 0.95, 95% CI 0.59–1.55, p = 0.85, and adjusted
OR 1.28, 95% CI 0.83–1.97, p = 0.26, respectively] alleles and
response to treatment.
The genotype distribution of all polymorphisms in both drug-
resistant and drug-responsive patients in the total group or in each
ethnic subgroup was consistent with HWE. There was no
signiﬁcant association between the ABCB1 (C1236T, G2677T,
C3435T) and PXR (G7635A) genotypes with response to drug
treatment in the total sample or in the Chinese and Malay
subgroups under alternative genetic models (Table 3). However,
the ABCB1 C3435T locus in the Indian subgroup showed a
signiﬁcant association with response to treatment under recessive
model (adjusted OR 0.38, 95% CI 0.16–0.86, p = 0.02). After
correction of multiple comparisons with Bonferroni’s method,
this signiﬁcant association was lost (0.05/4).
3.3. Haplotype association of ABCB1 and PXR polymorphisms with
response to treatment
Table 4 lists the eight possible haplotypes of ABCB1 poly-
morphisms in the drug-resistant and drug-responsive patients.
Overall, the TTT (22%) and the CGC haplotypes (20%) were more
Table 2
Genotypes and allele frequencies of ABCB1 and PXR polymorphisms of the drug-resistant (n=323) and drug-responsive (n=362) epilepsy patients and three ethnic
subgroups.
Allele/genotype Chinese (n=277) Indian (n=160) Malay (n=248) Total (685)
NR (%) R (%) NR (%) R (%) NR (%) R (%) NR (%) R (%)
ABCB1 C1236T
C 113 (43) 122 (42) 59 (44) 84 (45) 111 (44) 95 (39) 283 (44) 301 (42)
T 149 (57) 170 (58) 75 (56) 102 (55) 139 (56) 151 (61) 363 (56) 423 (58)
CC 27 (21) 28 (19) 14 (21) 20 (22) 24 (18) 22 (18) 65 (20) 70 (19)
CT 59 (45) 66 (45) 31 (46) 44 (47) 63 (46) 51 (41) 153 (47) 161 (45)
TT 45 (34) 52 (36) 22 (33) 29 (31) 38 (36) 50 (41) 105 (33) 131 (36)
ABCB1 G2677T
G 144 (55) 144 (49) 49 (37) 84 (45) 138 (55) 125 (51) 331 (51) 353 (49)
T 118 (45) 148 (51) 85 (63) 102 (55) 112 (45) 121 (49) 315 (49) 371 (51)
GG 36 (27) 35 (24) 8 (12) 18 (19) 39 (31) 25 (20) 83 (26) 78 (22)
GT 72 (55) 74 (51) 33 (49) 48 (52) 60 (48) 75 (61) 165 (51) 197 (54)
TT 23 (18) 37 (25) 26 (39) 27 (29) 26 (21) 23 (19) 75 (23) 87 (24)
ABCB1 C3435T
C 147 (56) 167 (57) 78 (58) 89 (48) 151 (60) 144 (58) 376 (58) 400 (55)
T 115 (44) 125 (43) 56 (42) 97 (52) 99 (40) 102 (42) 270 (42) 324 (45)
CC 39 (30) 49 (34) 23 (34) 17 (18) 47 (38) 44 (36) 109 (34) 110 (30)
CT 69 (53) 69 (47) 32 (48) 55 (59) 57 (46) 56 (45) 158 (49) 180 (50)
TT 23 (18) 28 (19) 12 (18) 21 (23) 21 (17) 23 (19) 56 (17) 72 (20)
PXR G7635A
G 152 (58) 180 (62) 74 (55) 101 (54) 159 (64) 164 (67) 385 (60) 445 (61)
A 110 (42) 112 (38) 60 (45) 85 (46) 91 (36) 82 (33) 261 (40) 279 (39)
GG 40 (30) 53 (36) 21 (31) 25 (27) 53 (42) 51 (42) 114 (35) 129 (36)
GA 72 (55) 74 (51) 32 (48) 51 (55) 53 (42) 62 (50) 157 (49) 187 (52)
AA 19 (15) 19 (13) 14 (21) 17 (18) 19 (15) 10 (8) 52 (16) 46 (13)
Abbreviations: NR, drug-resistance; R, drug-responsive.
B.S. Haerian et al. / Seizure 20 (2011) 387–394390frequent than other ABCB1 gene haplotypes. Similar results for the
TTT and CGC haplotypeswere observed in the Chinese (20 and 16%,
respectively) and Malay subgroups (23 and 22%, respectively), but
for only the TTT haplotype in the Indian subgroup (25%). Of the 27
possible diplotypes in total patients, CGC-TTT and TTT-TTT were
most frequent among diplotypes. However, in the Chinese
patients, TGC-TTT frequency was higher (14%) than other
diplotypes. Haplotypes and diplotypes in the total patients with
frequency of above 5% were encountered for association analysis.
The association between ABCB1 haplotypes and response to
treatment was not signiﬁcant in the overall or in the Chinese, but it
was signiﬁcant for the TTC haplotype in the Indian and Malay
subgroups (Table 4). However, after using 100,000 permutation
test and Bonferroni’s correction for multiple comparisons, these
associations were lost (p = 0.01 and p = 0.02 < 0.05/8, respective-
ly). No signiﬁcant association was observed between ABCB1
diplotypes and response to treatment in the overall or in each
ethnic subgroup. There was no strong LD between C1236T/
G2677T, G2677T/C3435T, and C1236T/C3435T polymorphisms in
the overall or in each ethnic subgroup. No signiﬁcant association of
ABCB1 and XPR gene interaction with response to treatment was
identiﬁed in the overall (cross-validation consistency = 10/10,
testing accuracy = 53.3%, p = 0.93) as well as in Chinese (testing
accuracy = 51.1%, p = 0.70), Indian (testing accuracy = 57.7%,
p = 0.42), and Malay (testing accuracy = 51.2%, p = 0.94) ethnic
subgroups.
4. Discussion
In the present study, we hypothesized that a relationship exists
between ABCB1 and PXR polymorphisms with response to AEDs in
theMalaysian epilepsy patients and its three stratiﬁed populations
by ethnicity. To examine this hypothesis, we analyzed alleles,
genotypes, and haplotypes of three loci at the ABCB1 gene (C1236T,
G2677T, and C3435T) and alleles and genotypes of one locus at the
PXR (G7635A) gene. We found no association between ABCB1
C1236T, G2677T/A, and C3435T polymorphisms and their haplo-
types with response to monotherapy with either CBZ or VPA in thetotal patients or in the Chinese, Indian and Malay subgroups
following permutation test and Bonferroni’s correction for multi-
ple comparisons in haploype analysis. No confounding factor was
proven thatmight affect the entire results of this association study.
Overall, the ﬁndings of C3435T polymorphism were consistent
with our meta-analysis for C3435T, but inconsistent with the
original report.8 The lack of association for the other two ABCB1
loci were compatible with all related studies of C1236T9,16–24 but
consistent with 9 previous studies9,16,18–20,22–24,33 and inconsis-
tent with 4 reports of on the G2677T locus.10,11,17,21
In this study, C1236 allele was less common than alternative
allele in each ethnicity, similar to the previous reports from
Asia.9,16–19,21–24 Higher and lower frequencies of the G2677 allele
than minor allele in the Chinese and Indian patients, respectively,
were more similar to their original ancestors.9,16,21,22,24 However,
G2677 allele in the Malays was more frequent than alternative
allele, consistent with the Chinese16,21 and Caucasian reports.9,33
The C3435 allele was more common in all three ethnicities, similar
to some Asian and Caucasian studies for the Chinese and Malays
but different of original ancestry in the Indians.8–11,33 Evidence
suggested that the high ancient genetic variation in the human
genome was lost during a severe bottleneck in the ancestors of
Europeans when they emigrated from Africa. Emergence of Asians
from Europe happened out of Africa. Despite of a common
ancestor, frequencies of genetic polymorphisms varies between
the Asians and Europeans. Since, prevalence of diseases varies
among populations, so it is expected that the frequencies of genetic
variants that contribute to their causation also vary. Geographic
and cultural factors can cause genetic variation in different
populations. This could be contributed by natural selection in a
speciﬁc local environment. When two geographically separate
populations are subject to distinct environmental or cultural
pressure, positive selectionmay change the allele frequency in one
population but not in another.34–36 It is plausible that high
variation of C3435T and G2677T polymorphisms among different
epilepsy patient populations is caused by these two factors.
We also analyzed the ABCB1 gene haplotypes derived from the
C1236T, G2677T, and C3435T polymorphisms in the epilepsy
Table 3
Genotypes and allele frequencies of ABCB1 and PXR polymorphisms in drug-resistant (n=323) and drug-responsive (n=362) epilepsy patients in the overall population studied and in the three ethnic subgroups under alternative
genetic models.
Genotype Ethnicity
Chinese (n=277) Indian (n=160) Malay (n=248) Total (685)
NR R p ORa (CI 95%) NR R p ORa (CI 95%) NR R p ORa (CI 95%) NR R p ORa (CI 95%)
C1236T
C vs. T 262 292 0.56 0.89 (0.61–1.30) 134 186 0.86 1.04 (0.64–1.70) 250 246 0.12 0.72 (0.48–1.09) 646 724 0.29 0.88 (0.69–1.11)
C/C vs. T/T 72 80 0.63 0.82 (0.37–1.83) 36 49 0.89 1.07 (0.41–2.81) 62 72 0.19 0.57 (0.25–1.32) 170 201 0.30 0.77 (0.48–1.23)
C/T vs. T/T 104 118 0.76 0.91 (0.50–1.66) 53 73 0.97 0.99 (0.44–2.20) 101 101 0.09 0.57 (0.29–1.09) 258 292 0.30 0.82 (0.56–1.19)
C/C+C/T vs. T/T 131 146 0.61 0.87 (0.50–1.51) 67 93 0.95 1.02 (0.49–2.13) 125 123 0.08 0.59 (0.32–1.07) 323 362 0.25 0.81 (0.57–1.16)
C/C vs. C/T+T/T 131 146 0.66 0.86 (0.44–1.69) 67 93 0.82 1.11 (0.47–2.59) 125 123 0.54 0.79 (0.37–1.68) 323 362 0.61 0.90 (0.59–1.37)
G2677T
G vs. T 262 292 0.11 0.73 (0.50–1.07) 134 186 0.07 1.60 (0.97–2.65) 250 246 0.51 0.87 (0.58–1.31) 646 724 0.79 0.97 (0.76–1.23)
G/G vs. T/T 59 72 0.41 0.71 (0.32–1.61) 34 45 0.10 2.53 (0.82–7.78) 65 48 0.38 0.66 (0.26–1.68) 158 165 0.85 0.95 (0.58–1.57)
G/T vs. T/T 95 111 0.09 0.55 (0.27–1.10) 59 75 0.16 1.82 (0.79–4.19) 86 98 0.29 1.50 (0.71–3.21) 240 284 0.55 1.13 (0.75–1.72)
G/G vs. (G/T+T/T) 131 146 0.06 0.54 (0.28–1.04) 67 93 0.08 1.98 (0.91–4.30) 125 123 0.58 1.23 (0.59–2.53) 323 362 0.71 1.08 (0.73–1.59)
(G/G+G/T) vs. T/T 131 146 0.39 0.77 (0.42–1.40) 67 93 0.18 1.95 (0.73–5.19) 125 123 0.11 0.57 (0.28–1.13) 323 362 0.41 0.85 (0.57–1.26)
C3435T
C vs. T 262 292 0.33 1.02 (0.83–1.75) 134 186 0.13 0.69 (0.42–1.12) 250 246 0.74 0.93 (0.62–1.40) 646 724 0.71 0.96 (0.75–1.21)
C/C vs. T/T 62 77 0.36 0.69 (0.31–1.53) 35 38 0.08 0.37 (0.12–1.14) 68 67 0.72 0.86 (0.37–2.01) 165 182 0.62 1.13 (0.69–1.85)
C/T vs. T/T 92 97 0.93 0.97 (0.46–2.05) 44 76 0.49 1.40 (0.54–3.60) 78 79 0.59 0.80 (0.36–1.77) 214 252 0.97 0.99 (0.62–1.58)
C/C+C/T vs. T/T 131 146 0.64 0.85 (0.42–1.70) 67 93 0.85 0.92 (0.38–2.20) 125 123 0.60 0.82 (0.39–1.72) 323 362 0.93 1.02 (0.66–1.57)
C/C vs. C/T+T/T 131 146 0.29 0.74 (0.42–1.29) 67 93 0.02 0.38 (0.16–0.86) 125 123 0.95 1.02 (0.55–1.87) 323 362 0.63 1.09 (0.76–1.57)
G7635A
G vs. A 262 292 0.86 1.03 (0.71–1.51) 134 186 0.85 0.95 (0.59–1.55) 250 246 0.26 1.28 (0.83–1.97) 646 724 0.60 1.07 (0.84–1.36)
G/G vs. A/A 59 72 0.98 0.99 (0.41–2.36) 35 42 0.92 1.06 (0.37–3.03) 72 61 0.15 0.48 (0.18–1.32) 166 175 0.50 1.20 (0.70–2.05)
G/A vs. A/A 91 93 0.90 0.95 (0.42–2.15) 46 68 0.63 0.79 (0.30–2.07) 72 72 0.26 1.75 (0.65–4.69) 209 233 0.44 0.82 (0.49–1.36)
G/G+G/A vs. A/A 131 146 0.94 0.97 (0.45–2.09) 67 93 0.76 0.87 (0.35–2.14) 125 123 0.16 1.92 (0.76–4.82) 323 362 0.45 1.20 (0.74–1.95)
G/G vs. G/A+A/A 131 146 0.76 0.92 (0.52–1.60) 67 93 0.59 1.23 (0.58–2.63) 125 123 0.53 0.83 (0.46–1.49) 323 362 0.83 0.96 (0.68–1.37)
Abbreviations: NR, drug-resistance; R, drug-responsive.
a OR estimated odds ratio by binary logistic regression analysis adjusted for age at study, onset age at epilepsy, etiology, ethnicity, gender, drug type, and seizure type.
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B.S. Haerian et al. / Seizure 20 (2011) 387–394392patients. Our negative results of haplotype analysis were consis-
tent with reports from India9,22,24 and Korea23 but inconsistent
with Austrian,12 Chinese,16 and Japanese studies.17 Unlike the
Indian drug-responsive patients, the TTT haplotype was more
frequent than others in overall and in the Chinese and Malays,
consistent with the Indian9,22,24 and Japanese17 reports but
inconsistent with the Austrian,12 Chinese,16 and Korean23 studies.
In these three studies, CGC was more common than other
haplotypes. We did not see any strong pairwise LD between the
C1236T-G2677T/A, G2677T/A-C3435T, and C1236T-C3435T poly-
morphisms. Our data was comparable with Austrian12 and Chinese
patients16 but for C1236T-G2677T/A polymorphisms in an Indian
study.9 High variation of pairwise LD in the ABCB1 gene and
C3435T loci frequency among different populations in the previous
reports could be referred to the proximity of this variant to the ﬁrst
hotspot of ABCB1 gene (Fig. 1) where crossing over happens.
Accordingly, crossing over events in this hotspot not only may be
involved with high variation of C3435T locus but also location of
this hotspotmay vary among the patient populations of the studies
in epilepsy.
We examined the association between PXR polymorphismwith
response to treatment in epilepsy, because it is reported being a
regulator of expression of the ABCB1 gene.37 A previous study
failed to show any association between PXR 11156 A > C and
11193 T > C polymorphisms with response to AEDs treatment in
Chinese epilepsy patients.19 We selected PXR G7635A polymor-
phism to examine the association of this locus with response to
AEDs in epilepsy because of three positive reports. One study
showed a strong association between this polymorphism with
susceptibility to inﬂammatory bowel disease and Crohn’s dis-
ease.26 Moreover, other two studies was performed in the renal
transplant recipients who received cyclosporine or prednisolone.
These studies demonstrated that the carriers of single G7635 allele
or in LDwith other alleles of PXR polymorphisms had lower plasma
concentration of these drugs than noncarriers due to higher
metabolic activity in the intestine.27,28 In contrast, our results did
not verify the role of this locus in epilepsy suggesting that the
G7635A polymorphismmay not contribute to response to AEDs in
Malaysian epilepsy patients.
There is inconsistency between the results of previous
association studies of some common polymorphisms of ABCB1
gene including C3435T with response to AEDs. A majority of these
reports used polytherapy (86%).8–11 Drug interaction or their
competition for interactionwith common transporters, targets and
metabolic mediators might be a plausible confounder factor in
these studies. For example, VPA interacts with CBZ, LTG, and
phenytoin.38 Therefore, we stringently selected 42% of all epilepsy
patients who were on monotherapy to have a homogenous
population and obtainmore reliable data.We focusedmore on VPA
and CBZ monotherapy as an inclusion criterion, since these drugs
are a widely used in epilepsy with a broad spectrum of activity.39
However, inclusion of this criterion in the study caused smaller
sample size than that in previous studies of subjects receiving
polytherapy but still much larger than other similar studies in
epilepsy patients on monotherapy. This gives a clearer picture of
the association study with more reliable data. Furthermore, we
applied adjusted ORs strategy for different variables including drug
type to minimize their effects on the association study.
Some reports suggested that CBZ and VPA are not substrates of
P-gp.40,41 We examined this hypothesis by using a homogenous
epilepsy population who are on either CBZ or VPA monotherapy
treatment. Thus, the present study that shows negative results of
the association of ABCB1 and PXR polymorphisms with drug
response, as well as their interaction, supported this hypothesis
that these two AEDs may not contribute to ABCB1. However, this
ﬁnding was inconsistent with a positive study (37.1%) of the
[()TD$FIG]
Fig. 1. Position of ABCB1 C1236T, G2677T/A, and C3435T loci between two recombination hotspots (black color).
B.S. Haerian et al. / Seizure 20 (2011) 387–394 393patients who were on CBZ monotherapy, while in studies in which
the patients were on polytherapy, VPA was commonly included
(53.8%).17 In contrast, VPA (35.8%) and CBZ (24.3%) one negative
study,42 or VPA (43.6%) in another one,43 were themost commonly
used drug in the polypharmacy treatment. The rest of the studies in
which patients were on polytherapy did not report a clear history
of AEDs in polypharmacy regimen of the patients. Our ﬁndings
suggest that although CBZ or VPA may induce P-gp expression and
function, this effect may indirectly contribute through other
mediators or in connection of these genes with other genes and
loci.43–45 Further studies are necessary to ﬁnd the probable link
between these genes and other genes or loci with response to VPA
and CBZ.
In conclusion, this study failed to show any association between
the ABCB1 (C1236T, G2677T, and C3435T) and PXR (G7635A)
polymorphisms with response to monotherapy with either CBZ or
VPA in either the overall Malaysian epilepsy patients studied or in
the ethnic subgroups. Our ﬁndings suggest that these loci may not
contribute to response to drug treatment in epilepsy.
Acknowledgements
We gratefully acknowledge the patients for their participation
in this study and also the staff of the UMMC and UNMMC for their
assistance in recruiting the patients. This work was supported by
the PS137/2008C and PS460/2010A grants from the University of
Malaya.
References
1. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of
medically intractable epilepsy. Epilepsia 2005;46(2):224–35.
2. Tishler DM,Weinberg KI, HintonDR, BarbaroN, Annett GM, Raffel C.MDR1 gene
expression in brain of patients with medically intractable epilepsy. Epilepsia
1995;36:1–6.
3. Lo¨scher W, Potschka H. Blood–brain barrier active efﬂux transporters: ATP-
binding cassette gene family. Epilepsia 2005:1–23.
4. Chin JE, Sofﬁr R, Noonan KE, Choi K, Roninson IB. Structure and expression of the
human MDR1 (P-gp) gene family. Mol Cell Biol 1989;9:3808–20.
5. Lo¨scher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmaco-
genetics on the treatment of epilepsy. Epilepsia 2009;50(1):1–23.
6. Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacoge-
nomics 2007;8(8):1075–80.
7. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the
human multidrug-resistance gene: multiple sequence variations and correla-
tion of one allele with P-glycoprotein expression and activity in vivo. Proc Natl
Acad Sci USA 2000;97:3473–8.
8. Haerian BS, Roslan H, Raymond AA, Tan CT, Zulkiﬂi SZ, Lim KS, et al. ABCB1
C3435T polymorphism and the risk of resistance to antiepileptic drugs in
epilepsy: a systematic review and meta-analysis. Seizure 2010;19:339–46.
9. Grover S, Bala K, Sharma S, Gourie-Devi M, Baghel R, Kaur H, et al. Absence of a
general association between ABCB1 genetic variants and response to antiepi-
leptic drugs in epilepsy patients. Biochimie 2010.
10. Sa´nchezMB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdiza´n EM, et al.Genetic
factors associated with drug-resistance of epilepsy: relevance of stratiﬁcation
by patient age and aetiology of epilepsy. Seizure 2010;19(2):93–101.
11. Alpman A, Ozkinay F, Tekgul H, Gokben S, Pehlivan S, Schalling M, et al.
Multidrug resistance 1 (MDR1) gene polymorphisms in childhood drug-resis-
tant epilepsy. J Child Neurol 2010.
12. Zimprich F, Sunder-Olassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich
A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in
temporal lobe epilepsy. Neurology 2004;63:1087–9.13. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, et al. Whole-
genome patterns of common DNA variation in three human populations.
Science 2005;307(5712):1072–9.
14. Frazer KA, Ballinger DG, Cox DR, et al. International_HapMap_Consortium: a
second generation human haplotype map of over 3.1 million SNPs. Nature
2007;449(7164):851–61.
15. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for
human evolutionary history and disease. Annu Rev Genomics Hum Genet
2003;4:293–340.
16. Hung CC, Tai JJ, Lin CJ, LeeMJ, Liou HH. Complex haplotypic effects of the ABCB1
gene on epilepsy treatment response. Pharmacogenomics 2005;6(4):411–7.
17. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorph-
isms inﬂuence the response to antiepileptic drugs in Japanese epilepsy patients.
Pharmacogenomics 2006;7(4):551–61.
18. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide
polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure
2006;15(1):67–72.
19. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in
NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics
2007;8(9):1151–8.
20. Shahwan A, Murphy K, Doherty C, Cavalleri GL, Muckian C, Dicker P, et al. The
controversial association of ABCB1 polymorphisms in refractory epilepsy: an
analysis of multiple SNPs in an Irish population. Epilepsy Res 2007;73(2):192–8.
21. Kwan P, Wong V, Ng PW, Lui CH, Sin NC, Poon WS, et al. Gene-wide tagging
study of association between ABCB1 polymorphisms and multidrug resistance
in epilepsy in Han Chinese. Pharmacogenomics 2009;10(5):723–32.
22. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Analysis of
genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of
medically refractory epilepsy in an Indian population. Drug Metab Pharmaco-
kinet 2009;24(3):255–60.
23. Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, Cho JY, et al. Lack of association between
ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in
partial epilepsy. Epilepsy Res 2009;84(1):86–90.
24. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No
association of ABCB1 polymorphisms with drug-refractory epilepsy in a north
Indian population. Epilepsy Behav 2009;14(1):78–82.
25. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3)
and their implications in drug metabolism and pharmacogenetics. Curr Drug
Metab 2005;6(4):369–83.
26. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, et al. The
pregnane X receptor locus is associated with susceptibility to inﬂammatory
bowel disease. Gastroenterology 2006;130(2):341–8. [quiz 592].
27. Fanta S, Jo¨nsson S, Karlsson MO, Niemi M, Holmberg C, Hoppu K, et al. Long-
term changes in cyclosporine pharmacokinetics after renal transplantation in
children: evidence for saturable presystemic metabolism and effect of NR1I2
polymorphism. J Clin Pharmacol 2010;50(5):581–97.
28. MiuraM, Satoh S, Inoue K, KagayaH, SaitoM, Inoue T, et al. Inﬂuence of CYP3A5,
ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal
transplant recipients. Steroids 2008;73(11):1052–9.
29. Commission on Classiﬁcation and Terminology of the International League
Against Epilepsy; 1981.
30. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al.
Deﬁnition of drug resistant epilepsy: consensus proposal by the ad hoc Task
Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009:1–9.
31. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, SchwabM, et al. Frequency
of single nucleotide polymorphisms in the P-glycoprotein drug transporter
MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69(3):169–74.
32. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJD, Chong SS, et al. Distinct haplotype
proﬁles and strong linkage disequilibrium at the MDR1 multidrug transporter
gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:
437–50.
33. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, et al.
Identifying candidate causal variants responsible for altered activity of the
ABCB1 multidrug resistance gene. Genome Res 2004;14(7):1333–44.
34. Marchani EE,WatkinsWS, Bulayeva K, Harpending HC, Jorde LB. Culture creates
genetic structure in the Caucasus: autosomal, mitochondrial, and Y-chromo-
somal variation in Daghestan. BMC Genet 2008;9:47.
35. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, Shamovsky O, et al.
Positive natural selection in the human lineage. Science 2006;312(5780):
1614–20.
36. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N
Engl J Med 2010;363(16):1551–8.
B.S. Haerian et al. / Seizure 20 (2011) 387–39439437. Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone
receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xeno-
biotics and endogenous compounds. Curr Drug Metab 2006;7(4):349–65.
38. Patsalos PN, Fro¨scher W, Pisani F, van Rijn CM. The importance of drug
interactions in epilepsy therapy. Epilepsia 2002;43(4):365–85.
39. Elger CE, Schmidt D. Modern management of epilepsy: a practical approach.
Epilepsy Behav 2008;12(4):501–39.
40. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamaz-
epine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51(4):
345–9.
41. Baltes S, Fedrowitz M, Torto´s CL, Potschka H, Lo¨scher W. Valproic acid is not
a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in
a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther
2007;320(1):331–43.42. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Ha¨sler R, et al. Non-
response to antiepileptic pharmacotherapy is associated with the ABCC2-
24C > T polymorphism in young and adult patients with epilepsy. Pharmaco-
genet Genomics 2009;19:353–62.
43. Szoeke C, Sills GJ, Kwan P, Petrovski S, Newton M, Hitiris N, et al. Multidrug-
resistance genotype (ABCB1) and seizure recurrence in newly treated epilepsy:
data from International Pharmacogenetic Cohorts. Epilepsia 2009.
44. Yang HW, Liu HY, Liu X, Zhang DM, Liu YC, Liu XD, et al. Increased P-
glycoprotein function and level after long-term exposure of four antiepileptic
drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett
2008;434(3):299–303.
45. Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The
antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in
human tumour cell lines and in rat liver. Br J Pharmacol 2006;149(3):250–60.
